Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Breast Center, Peking University Cancer Hospital & Institute, Beijing, China.
Breast Cancer Res Treat. 2018 Apr;168(2):365-370. doi: 10.1007/s10549-017-4591-z. Epub 2017 Dec 6.
This study aimed to determine the long-term prognosis of breast cancer patients with Tc-rituximab for sentinel lymph node biopsy (SLNB).
A total of 2947 patients with negative sentinel lymph nodes (SLNs) omitting axillary lymph node dissection (ALND), treated between June 2005 and December 2013, were retrospectively analyzed. SLNB was performed prior to adjuvant therapy.
After a median follow-up of 62 months, 22 cases of axillary recurrence (AR) were observed. The 5-year AR rate (ARR) was 0.7% [95% confidence interval (CI) 0.3-1.1%] and the 5-year relapse-free survival (RFS) was 95.2% (95% CI 94.4-96.0%). Multivariate analysis showed that abnormal axillary ultrasound with negative fine-needle aspiration (FNA) [hazard ratio (HR) 3.79, 95% CI 1.55-9.28; P = 0.004], not receiving radiotherapy (HR 4.38, 95% CI 1.47-13.05; P = 0.008), and age ≤ 40 years (HR 2.93, 95% CI 1.19-7.20; P = 0.020) were independent risk factors for AR.
ARR of SLNB-negative patients with Tc-rituximab is low. Abnormal axillary ultrasound with negative FNA, not receiving radiotherapy, and age ≤ 40 years were prognostic factors for higher ARRs.
本研究旨在确定 Tc-利妥昔单抗用于前哨淋巴结活检（SLNB）的乳腺癌患者的长期预后。
回顾性分析了 2005 年 6 月至 2013 年 12 月期间接受治疗的 2947 例阴性前哨淋巴结（SLN）且省略腋窝淋巴结清扫术（ALND）的患者。SLNB 在辅助治疗前进行。
中位随访 62 个月后，观察到 22 例腋窝复发（AR）。5 年 AR 率（ARR）为 0.7%（95%置信区间 0.3-1.1%），5 年无复发生存率（RFS）为 95.2%（95%置信区间 94.4-96.0%）。多因素分析显示，腋窝超声异常伴阴性细针抽吸（FNA）[风险比（HR）3.79，95%置信区间 1.55-9.28；P=0.004]、未接受放疗（HR 4.38，95%置信区间 1.47-13.05；P=0.008）和年龄≤40 岁（HR 2.93，95%置信区间 1.19-7.20；P=0.020）是 AR 的独立危险因素。
SLNB 阴性患者的 ARR 较低。腋窝超声异常伴阴性 FNA、未接受放疗和年龄≤40 岁是 ARR 较高的预后因素。
